BR112018073388A2 - tratamento de efeitos colaterais resultantes da quimodenervação - Google Patents
tratamento de efeitos colaterais resultantes da quimodenervaçãoInfo
- Publication number
- BR112018073388A2 BR112018073388A2 BR112018073388A BR112018073388A BR112018073388A2 BR 112018073388 A2 BR112018073388 A2 BR 112018073388A2 BR 112018073388 A BR112018073388 A BR 112018073388A BR 112018073388 A BR112018073388 A BR 112018073388A BR 112018073388 A2 BR112018073388 A2 BR 112018073388A2
- Authority
- BR
- Brazil
- Prior art keywords
- chemodenervation
- treatment
- side effects
- muscle
- anticholinesterase
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 101710138657 Neurotoxin Proteins 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
- 239000002581 neurotoxin Substances 0.000 abstract 1
- 231100000618 neurotoxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662336344P | 2016-05-13 | 2016-05-13 | |
PCT/US2017/032636 WO2017197382A1 (en) | 2016-05-13 | 2017-05-15 | Treating of side-effects resulting from chemodenervation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018073388A2 true BR112018073388A2 (pt) | 2019-07-02 |
Family
ID=60266879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018073388A BR112018073388A2 (pt) | 2016-05-13 | 2017-05-15 | tratamento de efeitos colaterais resultantes da quimodenervação |
Country Status (10)
Country | Link |
---|---|
US (2) | US11129822B2 (pt) |
EP (1) | EP3454855B1 (pt) |
JP (2) | JP2019515052A (pt) |
KR (2) | KR20220063197A (pt) |
CN (1) | CN109414434A (pt) |
AU (2) | AU2017263850A1 (pt) |
BR (1) | BR112018073388A2 (pt) |
CA (1) | CA3023408A1 (pt) |
IL (1) | IL262916A (pt) |
WO (1) | WO2017197382A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018370015A1 (en) * | 2017-11-15 | 2020-05-28 | Delnova, Inc, | Treatment of side effects of botulinum therapies |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925856A (en) * | 1987-07-28 | 1990-05-15 | Sri International | Aldoxime-substituted imidazolium derivatives useful in the treatment of poisoning by phosphorus-containing chemicals |
US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
US5622976A (en) * | 1991-12-31 | 1997-04-22 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
GB9410871D0 (en) * | 1994-05-31 | 1994-07-20 | Imperial College | Modification of tetanus toxin for use as a transport protein |
US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6759552B2 (en) * | 2002-03-28 | 2004-07-06 | Council Of Scientific And Industrial Research | Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species |
CN1260349C (zh) * | 2003-04-29 | 2006-06-21 | 云南省微生物研究所 | 南宁链霉菌 |
GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
US20080090808A1 (en) * | 2006-10-17 | 2008-04-17 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
WO2009036235A2 (en) * | 2007-09-12 | 2009-03-19 | Virginia Tech Intellectual Properties, Inc. | Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache) |
CN101386818B (zh) * | 2008-07-29 | 2011-01-19 | 中山大学 | 一种海洋真菌培养物的提取物及其制备方法和应用 |
JP5782439B2 (ja) * | 2009-07-24 | 2015-09-24 | リポテック, エセ.ア.Lipotec, S.A. | 筋肉収縮を抑制する化合物 |
KR101067153B1 (ko) * | 2009-10-16 | 2011-09-22 | 경상대학교산학협력단 | 뇌신경 세포 보호 활성 및 아세틸콜린에스테라제 저해 활성을 갖는 율피 추출물 및 그의 용도 |
CN102933200B (zh) | 2009-12-18 | 2015-11-25 | 莱迪杜德制药公司 | 包含磷脂的单相凝胶组合物 |
EP2720708A4 (en) * | 2011-06-20 | 2015-10-14 | Univ Saint Louis | AIMING AT THE NEUROMUSCULAR END PLATE FOR TREATMENT PURPOSES |
CN103524515B (zh) * | 2012-07-03 | 2016-07-06 | 浙江海正药业股份有限公司 | 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途 |
MX2015003035A (es) * | 2012-09-10 | 2015-09-21 | Ophirex Inc | Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual. |
US10500183B2 (en) * | 2014-06-19 | 2019-12-10 | Attillaps Holdings | Acetylcholinesterase inhibitors for treatment of dermatological conditions |
-
2017
- 2017-05-15 BR BR112018073388A patent/BR112018073388A2/pt not_active Application Discontinuation
- 2017-05-15 WO PCT/US2017/032636 patent/WO2017197382A1/en unknown
- 2017-05-15 AU AU2017263850A patent/AU2017263850A1/en not_active Abandoned
- 2017-05-15 US US16/099,581 patent/US11129822B2/en active Active
- 2017-05-15 KR KR1020227011091A patent/KR20220063197A/ko not_active IP Right Cessation
- 2017-05-15 KR KR1020187032859A patent/KR20190008225A/ko not_active Application Discontinuation
- 2017-05-15 EP EP17797017.5A patent/EP3454855B1/en active Active
- 2017-05-15 JP JP2019512184A patent/JP2019515052A/ja active Pending
- 2017-05-15 CN CN201780041576.4A patent/CN109414434A/zh active Pending
- 2017-05-15 CA CA3023408A patent/CA3023408A1/en active Pending
-
2018
- 2018-11-11 IL IL262916A patent/IL262916A/en unknown
-
2021
- 2021-09-15 US US17/475,576 patent/US20220175753A1/en not_active Abandoned
-
2022
- 2022-04-07 JP JP2022063952A patent/JP2022088660A/ja active Pending
-
2023
- 2023-03-24 AU AU2023201832A patent/AU2023201832A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2019515052A (ja) | 2019-06-06 |
US20220175753A1 (en) | 2022-06-09 |
EP3454855B1 (en) | 2023-12-20 |
US11129822B2 (en) | 2021-09-28 |
KR20190008225A (ko) | 2019-01-23 |
WO2017197382A1 (en) | 2017-11-16 |
EP3454855A1 (en) | 2019-03-20 |
AU2017263850A1 (en) | 2018-11-22 |
US20190183875A1 (en) | 2019-06-20 |
CN109414434A (zh) | 2019-03-01 |
JP2022088660A (ja) | 2022-06-14 |
KR20220063197A (ko) | 2022-05-17 |
IL262916A (en) | 2018-12-31 |
CA3023408A1 (en) | 2017-11-16 |
AU2023201832A1 (en) | 2023-04-27 |
EP3454855A4 (en) | 2019-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY189601A (en) | Treatment of beta-thalassemia using actrii ligand traps | |
PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
PH12019502201A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
MX2022011167A (es) | Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana. | |
MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
BR112019001457A2 (pt) | tratamento e prevenção de distúrbios do sono | |
BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
EA201590191A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и фампридина | |
MX2020010576A (es) | Derivados tri sustituidos de arilo y heteroarilo como moduladores de p13-kinasa y rutas de autofagia. | |
BR112018074299A2 (pt) | composições farmacêuticas compreendendo eteplirsen | |
MX2016004909A (es) | Composicion que contiene eugenol como principio activo para prevenir o tratar la dermatitis atopica. | |
BR112015022571A2 (pt) | método de tratamento de esteatose hepática | |
BR112018073388A2 (pt) | tratamento de efeitos colaterais resultantes da quimodenervação | |
JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
BR112016020556A8 (pt) | compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto | |
NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
MX2023005014A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
PH12016501215A1 (en) | Azaindole derivative | |
BR112016028402A2 (pt) | toxina botulínica para uso no tratamento da paratonia | |
CR20220072A (es) | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias | |
ECSP16095557A (es) | Métodos para tratar infecciones | |
WO2018030881A3 (ko) | 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도 | |
TW202416942A (zh) | 治療慢性發炎疾病的方法 | |
MX2022001200A (es) | Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15V | Prolongation of time limit allowed |
Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |